The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium

Journal of Clinical Pathology

Volumn 55, Issue 7, 2002, Pages 514-519

  Mourits, M J E ^a   Ten Hoor, K A ^a   Van der Zee, A G J ^a   Willemse, P H B ^a   De Vries, E G E ^a   Hollema, H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIUM CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENCE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA;

EID: 0036067081     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.55.7.514     Document Type: Article

References (36)

1. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers
2. Endometrial cancer following breast cancer: Effect of tamoxifen and castration by radiotherapy
3. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
4. Risk of endometrial cancer after tamoxifen treatment of breast cancer
5. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies
6. Second cancers after adjuvant tamoxifen therapy for breast cancer
7. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study
8. Effect of tamoxifen on endometrial proliferation
9. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen
10. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial
11. Endometrial lesions in patients undergoing tamoxifen therapy
12. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening
13. Pathology of endometrium treated with tamoxifen
14. Endometrium pathology in postmenopausal tamoxifen treatment: Comparison between gynaecologically symptomatic and asymptomatic breast cancer patients
15. Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen
16. Effect of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: A prospective long-term study using transvaginal ultrasound
17. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation
18. Immunoreactivity of human endometrium: Correlation with endometrial dating
19. Immunocytochemical analysis of oestrogen receptors and progesterone receptors in the human uterus throughout the menstrual cycle and after the menopause
20. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections
21. Autoclave heating: An alternative method for microwaving?
22. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer
23. Expression of steroid receptors, Ki-67, and epidermal growth factor receptor in tamoxifen-treated endometrium
24. Modulation of endometrial steroid receptors and growth regulatory genes by tamoxifen
25. Steroid receptor expression in endometria from women treated with tamoxifen
26. Adenosarcoma of the uterus following tamoxifen treatment for breast cancer
27. Alterations in steroid hormone receptors in the tamoxifen-treated endometrium
28. Common endometrial decidual reaction in postmenopausal breast cancer patients treated with tamoxifen and progestogens
29. The effects of norethisterone on endometrial abnormalities identified by transvaginal ultrasound screening on healthy post-menopausal women on tamoxifen or placebo
30. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: A randomised controlled trial
31. Estrogen and progesterone receptor expression in postmenopausal tamoxifen-exposed endometrial pathologies
32. DNA ploidy, cell proliferation and steroid hormone receptors in endometrial hyperplasia and early adenocarcinoma
33. High-grade endometrial carcinoma in tomoxifen-treated breast cancer patients
34. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features
35. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
36. Gynaecological effects of tamoxifen